NCT02253342View on ClinicalTrials.gov

Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

August 31, 2015

Conditions

Intrapulmonary Pharmacokinetics of WCK 2349

Interventions

DRUG

WCK-2349

Each subject will receive ten oral doses of 1000 mg WCK 2349 administered twice-daily starting on Day 1

Trial Locations (1)

85006

Pulmonary Associates, 1112 E. McDowell Rd., Phoenix

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Clinartis

INDUSTRY

lead

Wockhardt

INDUSTRY